Nutraceuticals and cholesterol-lowering action

Publication date: Available online 22 November 2014 Source:IJC Metabolic & Endocrine Author(s): Arrigo F.G. Cicero , Angelo Parini , Martina Rosticci Nutraceuticals play an important role in cardiovascular prevention in patients with dyslipidemia. Many scientific studies support use of these substances alone or associated with other drugs in clinical practice. Specifically, monacolines, berberine, policosanol and gamma-oryzanol could significantly reduce cholesterolemia. However, there is still an insufficient number of studies demonstrating morbility and morbidity outcomes of nutraceuticals, nor are sufficient data regarding the use of nutraceuticals in different types of patients, on tolerability, safety, target population, modality and duration of use present in literature.
Source: IJC Metabolic and Endocrine - Category: Endocrinology Source Type: research